Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study.
Cai X, Ji L, Yuan M, Ma J, Bian F, Li S, Pang W, Yan S, Zhou H, Hou M, Li W, Jia Y, Liu L, Ding K, Xu M. Cai X, et al. Among authors: pang w. Lancet Reg Health West Pac. 2024 Oct 3;51:101197. doi: 10.1016/j.lanwpc.2024.101197. eCollection 2024 Oct. Lancet Reg Health West Pac. 2024. PMID: 39430684 Free PMC article.
Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII).
Ji L, Wan H, Wen B, Wang X, Wang J, Bian R, Pang W, Tian J, Wang Y, Bian F, Gao Z, Condoleon A, Feng W, Zhang X, Cui N. Ji L, et al. Among authors: pang w. Diabetes Obes Metab. 2020 May;22(5):838-846. doi: 10.1111/dom.13967. Epub 2020 Feb 18. Diabetes Obes Metab. 2020. PMID: 31944546 Free PMC article. Clinical Trial.
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
Ji L, Agesen RM, Bain SC, Fu F, Gabery S, Geng J, Li Y, Lu Y, Luo B, Pang W, Tao Y; PIONEER 12 investigators. Ji L, et al. Among authors: pang w. Diabetologia. 2024 Sep;67(9):1800-1816. doi: 10.1007/s00125-024-06133-4. Epub 2024 Jul 10. Diabetologia. 2024. PMID: 38985161 Free PMC article. Clinical Trial.
Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial.
Ji L, Gao Z, Shi B, Bian R, Yin F, Pang W, Gao H, Cui N. Ji L, et al. Among authors: pang w. Adv Ther. 2018 Jun;35(6):864-874. doi: 10.1007/s12325-018-0717-x. Epub 2018 Jun 5. Adv Ther. 2018. PMID: 29873004 Free PMC article. Clinical Trial.
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Yuan X, Guo X, Zhang J, Dong X, Lu Y, Pang W, Gu S, Niemoeller E, Ping L, Nian G, Souhami E; LixiLan-L-CN investigators. Yuan X, et al. Among authors: pang w. Diabetes Obes Metab. 2022 Nov;24(11):2182-2191. doi: 10.1111/dom.14803. Epub 2022 Jul 25. Diabetes Obes Metab. 2022. PMID: 35762489 Free PMC article. Clinical Trial.
1,507 results